Related Experiment Video
Updated: Jan 1, 2026
06:21
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
10.9K
Metabolic Disturbances in Children Treated for Solid Tumors
Ewa Barg1, Joanna Połubok2, Marta Hetman2
1Department of Basic Medical Sciences, Wroclaw Medical University, 50-560 Wroclaw, Poland.
Nutrients
|December 19, 2019
Summary
Pediatric patients treated with anti-cancer therapy (ACT) frequently develop metabolic disturbances. Post-ACT patients show significantly higher risks of dyslipidemia and atherosclerosis compared to controls, necessitating regular monitoring.
Area of Science:
- Pediatric Oncology
- Endocrinology
- Metabolic Disorders
Background:
- Metabolic disturbances are common in children post-cancer treatment.
- Anti-cancer therapy (ACT) can lead to long-term health issues.
- Assessing metabolic health after ACT is crucial for patient outcomes.
Purpose of the Study:
- To determine the prevalence of metabolic disturbances in pediatric patients following ACT.
- To compare metabolic parameters in patients post-ACT versus a control group.
- To identify specific risks for dyslipidemia and atherosclerosis in this population.
Main Methods:
- Study included 44 pediatric patients treated for solid tumors and 31 controls.
- Evaluated body weight, height, BMI, and lipid parameters using Standard Deviation Scores (SDS).
- Calculated atherosclerosis risk indicators and compared lipid profiles between sexes and groups.
Main Results:
- Obesity/overweight affected one-third of patients post-ACT.
- Hypercholesterolemia was present in 50%, elevated triglycerides (TG) SDS in 11%, and elevated LDL-C SDS in 9%.
- The study group exhibited a 150-fold higher risk ratio for lipid disorders compared to controls.
Conclusions:
- Pediatric patients after ACT have a substantially elevated risk of dyslipidemia and atherosclerosis.
- Regular monitoring of lipid profiles and thyroid function is essential for these patients.
- Early detection and management can mitigate long-term cardiovascular risks.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
154
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
154
01:20Inborn Errors of Metabolism
662
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
662
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
196
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
196
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
173
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
173
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
210
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
210
01:21Overview of Protein Metabolism
3.5K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
3.5K